{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-011391","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2025-05-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.853371+00:00","generated_at":"2026-05-21T02:38:45.117296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspira Q1 revenue up 5.9% to $2.28M; gross margin 68.5%, cash burn reduced 30%","bullets":["Revenue $2.28M vs $2.15M YoY (+5.9%), driven by select price increases and 94% jump in sales per FTE.","Gross profit $1.6M (+28.5%); gross margin improved to 68.5% from 56.4% due to one-time accrual reduction and OvaWatch profitability.","Operating expenses fell 19% to $4.8M (vs $5.9M); operating cash burn reduced 30% to $3.1M.","Cash on hand rose to $3.3M from $1.8M; current liabilities decreased 30% to $3.8M.","CEO Mike Buhle cited early traction under new leadership; ENDOInform R&D updates expected by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-011391","json":"https://secwatch.observer/filing/0001641172-25-011391.json","markdown":"https://secwatch.observer/filing/0001641172-25-011391.md","text":"https://secwatch.observer/filing/0001641172-25-011391.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000164117225011391/0001641172-25-011391-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000164117225011391/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T02:38:45.117296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}